Anergis Appoints Jacques-François Martin as Chairman of the Board of Directors
EPALINGES, Switzerland – February 1st, 2012 – Anergis, a clinical-stage biopharmaceutical company developing novel allergy vaccines, today announced the appointment of Jacques-François Martin, Chairman and CEO of vaccine company Mymetics, as Chairman of the Board of Directors.Anergis develops allergy vaccines based on its proprietary technology of “Contiguous Overlapping Peptides” (“COPs”). Anergis’ lead allergy vaccine, called “AllerT”, is in clinical Phase IIb development and is designed to provide ultra-fast and safe desensitization to birch pollen allergy, a widespread condition in developed countries. Anergis’ vaccines are designed to provide long-term protection against allergies with a 2-month treatment.
“Anergis´ technology and products clearly have the potential to be game-changing in the treatment of allergies and I am delighted to contribute to the development of the company together with its management and Board of Directors,” said Jacques-François Martin. Mr. Martin takes over the function from Dr. Markus Hosang, General Partner at BioMedPartners AG, Switzerland, who had served as interim Chairman since July 2011 and who will remain a Member of the Board.
“We are very pleased and honored to welcome Jacques-François Martin to the Board of Directors. Mr. Martin brings a very rich business management and development experience from the vaccine industry, where he held a number of critical senior executive positions, and we look forward to working with him to continue the fast-paced development of Anergis,” added Vincent Charlon, Chief Executive Officer of Anergis.
Jacques-François Martin is Chairman and CEO of Mymetics Corporation. Previously, he was CEO of Chiron Vaccines (now Novartis) from 1991 to 1993 and CEO of Pasteur-Mérieux (now Sanofi-Pasteur) from 1988 to 1991. In addition, he held leadership positions with not‐for‐profit organizations dedicated to the development of vaccines for debilitating and life-threatening diseases in both developed nations and third world countries. Among others, he was the first President and CEO of The Vaccine Fund (Bill and Melinda Gates Foundation) from 2000 to January 2005 and a member of the Board of the International AIDS Vaccine Initiative (IAVI) from November 1997 to June 2003. He started his executive career as Chief Executive Officer of Rhône-Poulenc Pharma in Hamburg, Germany, in 1970. Mr. Martin is a member of the French Academy of Technologies and an officer in the French Order of Merit.
###
About Anergis:
Anergis SA is a Swiss-based biopharmaceutical company specializing in the discovery and development of novel allergy vaccines targeting the most frequent allergies.
Allergies are the most prevalent and the fastest growing chronic condition in the industrialized world, with over 300 million people affected. While short-term symptomatic treatments of allergies need to be prescribed continuously, the only curative therapy, known as “desensitization” or “Specific Immunotherapy” (SIT), is a process of induction of tolerance to the allergen that today requires 3-5 years of treatment and poses the risk of serious side effects.
Anergis is developing innovative SIT products based on its proprietary Contiguous Overlapping Peptides (“COPs”) technology. In contrast to conventional desensitization treatments, COPs can be safely administered at high doses to induce tolerance to the allergen after few injections only. Studies of COPs targeting bee venom and birch pollen allergies in both animals and humans have demonstrated excellent safety (no immediate allergic reaction) and immunogenicity (production of specific antibodies and cytokines against the original allergen and establishment of a long-term immune memory). Anergis’ lead-product is currently in Phase IIb clinical development.
Anergis raised CHF 18 million in March 2011 from lead investors Vinci Capital, Sunstone Capital, BioMedInvest and other investors, including Esperante Ventures and Defi Gestion.
Mr. Vincent Charlon
Anergis SA
Biopôle III
Route de la Corniche 9B
CH-1066 Epalinges
Switzerland
Tel: +41 21 651 92 20
Fax: +41 21 651 92 21
info(at)anergis.ch
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anergis Appoints Jacques-François Martin as Chairman of the Board of Directors here
News-ID: 209232 • Views: …
More Releases from Anergis SA
Anergis and Virometix Announce Research Collaboration to Use Synthetic Virus-Lik …
- Study is performed at the Helmholtz Centre for Infection Research and supported by a TRANSVAC2 grant -
Epalinges, Switzerland, July 09, 2020 – Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs, announced today that they have entered into a research collaboration. The study will be conducted at the Helmholtz Centre for…
Anergis Reports Positive Preclinical Proof-of Concept Data of the Second-Generat …
- The second-generation COP Allergy Vaccines met the preset success criteria: strong TH1 response, absence of IgE response and excellent tolerability
- Anergis will raise new financing to conduct clinical trials with the second-generation COP Allergy Vaccines as soon as possible
EPALINGES, Switzerland, December 13th, 2018 – Anergis, a company developing proprietary ultra-fast Allergy Immunotherapy (AIT), announced today that the Company has successfully completed the mice proof-of-concept study…
More Releases for Martin
CubeSat Market 2019-2023: Lockheed Martin, Lockheed Martin, The Boeing, GomSpace …
CubeSat Market Research Report: Information by Size (O.25u-1U, 2U), Subsystem (Payloads, Structures), Application (Earth Observation & Traffic Monitoring, Communication), End User (Commercial, Non-Profit Organization), and Region — Global Forecast till 2023
The CubeSat market is estimated to register a CAGR of approximately 19.83% during the forecast period of 2018 to 2023.
Market Highlights
CubeSats offer advanced functionalities such as automated data gathering, warning systems, and enhanced imaging capabilities. These functions assist scientists in…
Global Pet Grooming Products Market 2025 - Beaphar, Ancol Pet Products Limited, …
The newly published report on Pet Grooming Products Market is designed to benefit several industry people including the governments, commercials, manufacturers, residential & industrial consumers and other stakeholders to diversify their Pet Grooming Products market-centric strategies in proportion to the estimated and enduring trends in the industry besides allowing them in strategizing investments and capitalizing on market opportunities.
Download Free sample copy of this report: https://www.statsandreports.com/request-sample/226156-global-pet-grooming-products-market-data-survey-report-2025
The report focuses on several key…
C4ISR Market Forecasts – Lockheed Martin Corporation, Boeing
MarketStudyReport.com Add New Global C4ISR Market by Manufacturers, Countries, Type and Application, Forecast to 2023 to its research database. The report presents a deep study of the market growth factors and drivers. The report spread across 103 pages with table and figures in it.
"""C4ISR is a military terminology, it is by the C2 (Command, Control) evolved, usually translated as command automation system. It is abbreviated of Command, Control, Communications, Computers,…
RAPID: Lockheed Martin Approved
Nashua, NH – April 4, 2016 – RAPID was announced as an approved vendor for Lockheed Martin as of April 2016. RAPID has been working with Lockheed Martin divisions for a number of years, but the addition to the Approved Vendor list will strengthen and build upon the existing relationship.
Lockheed Martin is an aerospace, defense, security, and advanced technology company that employs over 116,000 professionals worldwide. Lockheed Martin has…
Lockheed Martin integrate Perle Fiber Media Converters
Perle Systems, a global provider of advanced Ethernet over fiber and secure device networking solutions, reveals that Lockheed Martin chose Perle Fiber Media Converters to provide copper to fiber conversion in a harsh Data Imagery application.
“I knew that I needed a Media Converter and as soon as I realised that Perle was able to provide it, the choice was a no brainer,” explained John Rumbles, Engineer at Lockheed Martin.“I was…
JEREMY MARTIN AWARDED CERTIFIED GRADUATE BUILDER
Austin, TX, March 22, 2010 – Jeremy Martin, of RisherMartin Renovations in Austin, Texas, recently became one of the select group of professional builders nationwide who have earned the Certified Graduate Builder (CGB) designation, identifying him as one of the building industry’s top professionals.
Administered by the National Association of Home Builders (NAHB) University of Housing, the CGB program is sponsored locally by the Home Builders Association of Greater Austin.
CGBs earn…